The effectiveness and safety of certolizumab pegol in clinical practice

The effectiveness and safety of certolizumab pegol in clinical practice - The effectiveness and safety of certolizumab pegol in clinical practice

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015441

Enrollment

400

Registered

2014-11-01

Start date

2014-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with rheumatoid arthritis diagnosed with 1987 ACR or 2010 ACR/EULAR classification criteria 2.Patients with rheumatoid arthritis who meet the guideline about the usage of TNF inhibitors by JCR 3.Patients who will receive CZP treatment 4.Patients who submit the written informed consent to participate in this study

Exclusion criteria

Exclusion criteria: 1.Patients complicated with serious infection 2.Patients with active tuberculosis 3.Patients allergic to the drug 4.Patients complicated with demyelinating disease or have a history of i 5.Patients with congestive heart failure 6.Patients contraindicated to the treatment with TNF inhibitors by the guideline about the usage by JCR 7.Patients their doctors find not appropriate for this study

Design outcomes

Primary

Measure	Time frame
Remission (SDAI<= 3.3) rate at week 52	—

Countries

Japan

Contacts

Public ContactYuko Kaneko

Keio University School of Medicine Division of Rheumatology, Department of Internal Medicine

ykaneko@z6.keio.jp03-3353-1211

Outcome results